全文获取类型
收费全文 | 5900篇 |
免费 | 351篇 |
国内免费 | 66篇 |
专业分类
耳鼻咽喉 | 64篇 |
儿科学 | 140篇 |
妇产科学 | 63篇 |
基础医学 | 780篇 |
口腔科学 | 70篇 |
临床医学 | 343篇 |
内科学 | 1683篇 |
皮肤病学 | 63篇 |
神经病学 | 414篇 |
特种医学 | 234篇 |
外科学 | 1117篇 |
综合类 | 20篇 |
预防医学 | 175篇 |
眼科学 | 88篇 |
药学 | 295篇 |
中国医学 | 3篇 |
肿瘤学 | 765篇 |
出版年
2024年 | 5篇 |
2023年 | 46篇 |
2022年 | 126篇 |
2021年 | 212篇 |
2020年 | 120篇 |
2019年 | 153篇 |
2018年 | 215篇 |
2017年 | 157篇 |
2016年 | 195篇 |
2015年 | 197篇 |
2014年 | 247篇 |
2013年 | 286篇 |
2012年 | 487篇 |
2011年 | 456篇 |
2010年 | 280篇 |
2009年 | 224篇 |
2008年 | 359篇 |
2007年 | 310篇 |
2006年 | 335篇 |
2005年 | 324篇 |
2004年 | 309篇 |
2003年 | 318篇 |
2002年 | 291篇 |
2001年 | 54篇 |
2000年 | 37篇 |
1999年 | 63篇 |
1998年 | 80篇 |
1997年 | 68篇 |
1996年 | 55篇 |
1995年 | 47篇 |
1994年 | 29篇 |
1993年 | 36篇 |
1992年 | 29篇 |
1991年 | 29篇 |
1990年 | 22篇 |
1989年 | 10篇 |
1988年 | 9篇 |
1987年 | 9篇 |
1986年 | 8篇 |
1985年 | 10篇 |
1984年 | 10篇 |
1983年 | 9篇 |
1982年 | 12篇 |
1981年 | 10篇 |
1980年 | 7篇 |
1979年 | 3篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1974年 | 3篇 |
排序方式: 共有6317条查询结果,搜索用时 15 毫秒
91.
Evaluation of the efficacy of an Helicobacter pylori eradication treatment for idiopathic thrombocytopenic purpura patients] 总被引:1,自引:0,他引:1
Atsunaga Kato Hideaki Kato Noboru Hirashima Tomoyuki Sakamoto Haruhiko Nukaya Kiyoaki Ito Seijiro Matsunaga Hiromu Kondo Yoshito Tanaka Kenji Sakakibara 《Nihon Shokakibyo Gakkai zasshi》2004,101(11):1209-1216
The relationship between Helicobacter pylori (H. pylori) and gastric diseases (e.g. peptic ulcer, MALT lymphoma, and stomach cancer) has been widely accepted. Recent studies have also suggested an association between H. pylori infection and idiopathic thrombocytopenic purpura (ITP). In this study, an H. pylori eradication treatment was administered to 20 ITP patients and elucidated for its effectiveness. Among those 20 patients, H. pylori infection was confirmed in 17 (85%) through a C14 urea breath test, a rapid urease test, or a culture examination of a biopsied sample obtained by gastrointestinal endoscopy. Although the other 3 were negative to H. pylori, the H. pylori eradication treatment was also attempted because no other effective treatments had been established at the time of this study. In the H. pylori eradication treatment, lansoprazole (LPZ) 60 mg bid, amoxicillin (AMPC) 1500 mg bid, and clarithromycin (CAM) 400 mg bid were given to each patient for 7 days. For 4 cases, CAM was replaced with metronidazole (MNZ) 750 mg bid. The patients whose H. pylori infection was not eradicated after the first treatment received the re-eradication treatment with LPZ 60 mg bid, AMPC 1500 mg bid, and MNZ 750 mg bid for 7 days. After the treatments, the success of eradicating H. pylori was confirmed in all 17 H. pylori positive patients. In addition, platelet recovery was obtained in 11/20 patients (55%), which included 2 H. pylori negative patients and 2 patients whose H. pylori eradication was not successful after the first treatment. No relationship was found between the eradication effectiveness and the following clinical parameters: age, gender, previous therapies, disease duration, presence of anti-nucleus antibody, endoscopic atrophic change in the stomach, or kinds of antibiotics used for the treatment. These results support the efficacy of an H. pylori eradication treatment for ITP patients. A noteworthy result of this study was that an increase of platelet count was observed not only in H. pylori positive ITP patients, but also in 2 out of 3 H. pylori negative ITP patients after H. pylori eradication. Further studies are required to elucidate the efficacy of H. pylori eradication therapy in the patients negative for H. pylori. 相似文献
92.
Cyclic Stretch Augments Production of Neutrophil Chemokines,Matrix Metalloproteinases,and Activin A in Human Endometrial Stromal Cells 下载免费PDF全文
93.
G‐cell hyperplasia of the stomach induces ECL‐cell proliferation in the pyloric glands in a paracrinal manner 下载免费PDF全文
Atsuko Kasajima Fumiyoshi Fujishima Takanori Morikawa Shuhei Kawasaki Sachiko Konosu‐Fukaya Yukiko Shibahara Tadaho Nakamura Takeo Yoshikawa Katsunori Iijima Tomoyuki Koike Mika Watanabe Chikashi Shibata Hironobu Sasano 《Pathology international》2015,65(5):259-263
An inhibitory mechanism toward gastrin hypersecretion is significantly different between G‐cell hyperplasia and gastrinoma despite the common clinical manifestations; hypergastrinemia and its related persistent gastric ulcers. We recenlty studied the G‐cell, d ‐cell and ECL‐cell density in a case of G‐cell hyperplasia. The 70‐year‐old patient has been treated for persistent gastric ulcers with a markedly increased plasma gastrin (5600 pg/mL). The stomach was surgically resected because of the obstruction associated with ulcer scars. The number of G‐cells in the pyloric glands was quantified on the surgical specimens and G‐cell hyperplasia was histolopathologically identified. Immunostainig of histidine decarboxylate revealed the presence of ECL‐cell hyperplasia in the pyloric glands and its density was significantly and positively correlated with G‐cell density. Somatostatin immunoreactive cells (d ‐cells) increased in their number in the oxyntic glands. These results all indicated that hypersecretion of gastrin in G‐cell hyperplasia could induce ECL‐cell proliferation in a paracrinal manner. In addition, relatively non‐prominent endocrinological features in the G‐cell hyperplasia compared to gastrinoma could be also related to the paracrinal somatostatin inhibitory effects upon ECL‐cells in the pyloric glands. 相似文献
94.
In lead optimization, it is difficult to estimate when an analog series might be saturated and synthesis of additional compounds would be unlikely to yield further progress. Rather than terminating a series, one often continues to generate analogs hoping to reach the final optimization goal, even if obstacles that are faced ultimately prove to be unsurmountable. Clearly, methodologies to better understand series progression and saturation are highly desirable. However, only a few approaches are currently available to monitor series progression and aid in decision making. Herein, we introduce a new computational method to assess progression saturation of an analog series by relating the properties of existing compounds to those of synthetic candidates and comparing their distributions in chemical space. The neighborhoods of analogs are analyzed and the distance relationships between existing and candidate compounds quantified. An intuitive dual scoring scheme makes it possible to characterize analog series and their degree of progression saturation.Chemical space view of an analog series. Shown are inactive (red) and active (blue) analogs together with virtual candidate compounds (green) available to expand the series. Chemical neighborhoods of analogs are depicted in gray. 相似文献
95.
Takashi Hanzawa Tadao Matsunaga Tomoyuki Koike Atsushi Kanno Atsushi Masamune Katsunori Iijima 《Minimally invasive therapy & allied technologies》2018,27(4):226-232
Introduction: Although measuring the pressure of the sphincter of Oddi and the bile duct is considered to be an important examination, called Sphincter of Oddi manometry (SOM), some complications related to the SOM device remain unsolved.Material and methods: To decrease adverse complications, we developed a 0.46?mm manometry and we performed some in vitro studies.Results: We successfully developed a 0.46?mm SOM. The diameter is the thinnest size used in endoscopic examinations. The results of in vitro studies show the suitability as SOM.Conclusion: This device will decrease the risks related to SOM examination. To confirm the safety and feasibility, further studies including in vivo studies will be needed. 相似文献
96.
97.
98.
Ippei Ikushima Lene Jensen Anne Flint Tomoyuki Nishida Jeppe Zacho Shin Irie 《Advances in therapy》2018,35(4):531-544
Introduction
Semaglutide is a glucagon-like peptide-1 analogue for once-weekly subcutaneous treatment of type 2 diabetes. This trial compared the pharmacokinetics, pharmacodynamics, and safety of semaglutide in Japanese and Caucasian subjects.Methods
In this single-center, double-blind, parallel-group, 13-week trial, 44 healthy male subjects (22 Japanese, 22 Caucasian) were randomized within each race to semaglutide 0.5 mg (n = 8), 1.0 mg (n = 8), placebo 0.5 mg (n = 3) or 1.0 mg (n = 3). The primary endpoint was semaglutide exposure at steady state [area under the curve (AUC0–168h)].Results
Steady-state exposure of semaglutide was similar for both populations: AUC0–168h estimated race ratio (ERR), Japanese/Caucasian: 0.5 mg, 1.06; 1.0 mg, 0.99; maximum concentration (Cmax) ERR: 0.5 mg, 1.06; 1.0 mg, 1.02. Exposure after the first dose (0.25 mg) was slightly higher in Japanese versus Caucasian subjects (AUC0–168h ERR 1.11; Cmax ERR 1.14). Dose-dependent increases in AUC0–168h and Cmax occurred in both populations. Accumulation was as expected, based on the half-life (t1/2, ~ 1 week) and dosing interval of semaglutide. Significant body weight reductions were observed with semaglutide 0.5 mg and 1.0 mg in Japanese (both p ≤ 0.05) and Caucasian (both p ≤ 0.05) subjects versus placebo. No new safety issues were identified.Conclusions
The pharmacokinetic, pharmacodynamic, and safety profiles of semaglutide were similar in Japanese and Caucasian subjects, suggesting that no dose adjustment is required for the clinical use of semaglutide in Japanese subjects.Funding
Novo Nordisk A/S, Denmark.Trial registration
ClinicalTrials.gov identifier NCT02146079. Japanese trial registration number JapicCTI-142550.99.
Masahiro Saito Tomoyuki Koike Yasuaki Abe Kenichiro Nakagawa Takeshi Kanno Xiaoyi Jin Waku Hatta Kaname Uno Naoki Asano Akira Imatani Fumiyoshi Fujishima Atsushi Masamune 《Internal medicine (Tokyo, Japan)》2021,60(3):391
We herein report the first case of foveolar-type gastric adenocarcinoma that developed after the initiation of vonoprazan (VPZ). A 51-year-old man had heartburn at the first visit and reflux esophagitis endoscopically, so he started taking VPZ. An approximately 5-mm-sized reddish polyp with a raspberry-like morphology was detected at the anterior wall of the upper body of the stomach 156 weeks after starting maintenance therapy with VPZ 10 mg/day. It was diagnosed as foveolar-type gastric adenocarcinoma based on a biopsy. Another approximately 4-mm-sized foveolar-type gastric adenocarcinoma was also detected at the posterior wall of the middle body of the stomach. 相似文献
100.